

## Product Information

# SILu™ Prot ALB, Albumin, Human Recombinant, Expressed in HEK Cells SIL MS Protein Standard, <sup>13</sup>C- and <sup>15</sup>N-labeled

**MSST0011**

Storage temperature -20 °C

## Product Description

SILu™ Prot ALB is a recombinant, stable isotope-labeled human albumin which incorporates [<sup>13</sup>C<sub>6</sub>, <sup>15</sup>N<sub>4</sub>]-Arginine and [<sup>13</sup>C<sub>6</sub>, <sup>15</sup>N<sub>2</sub>]-Lysine. Expressed in human 293 cells, it is designed to be used as an internal standard for bioanalysis of albumin in mass spectrometry. SILu™ Prot ALB is a monomer of 607 amino acids (including C-terminal polyhistidine and FLAG® tags), with a calculated molecular mass of 69.6 kDa.

Albumin is synthesized exclusively by the liver parenchymal cells at a rate of 14 g/day.<sup>1</sup> While it is the most abundant plasma protein (> 50%),<sup>1</sup> increased urine albumin concentrations indicate bleedings in the lower urinary tract (ureter, bladder) or infections of the renal pelvis.<sup>2</sup> A small abnormal albumin excretion is known as microalbuminuria and serves as an indicator for temporary overload of the glomerular filtration (fever, excessive sports)<sup>3</sup> or chronic injury of the glomeruli (diabetes).<sup>4</sup>

Each vial contains 10–13 µg of SILu™ Prot ALB standard, lyophilized from a solution of phosphate buffered saline. Vial content was determined by the Bradford method using BSA as a calibrator. The correction factor from the Bradford method to Amino Acid Analysis is 75% for this protein.

**Identity:** Confirmed by peptide mapping**Purity:** ≥ 95% (SDS-PAGE)**Heavy amino acid incorporation efficiency:** ≥ 98% (MS)**UniProt:** P02768

## Sequence Information

The C-terminal polyhistidine and FLAG® tags are italicized.

RRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDH  
VKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATL  
RETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEV  
DVMCTAFHDNEETFLKKYLYEIAARRHPYFYAPELLFFAKRYK  
AAFTECCQAADKAACLLPKLDELDEGKASSAKQRLKCS  
LQKFGERAFAKAWAVARLSQRFPAEFAEVSKLVTDLTQVHT  
ECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLL  
EKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKD  
VFLGMFLYEYARRHPDYSVLLLRLLAKTYETTLEKCCAAADP  
HECYAKVFDEFKPLVEEPQNLKQNCLEFQGEYKFQNAL  
LVRYTKKVPQVSTPTLVEVSRNLGKVGSKCKHPEAKRMP  
CAEDYLSVVLNQLCVLHEKTPVSDRVTCKCTESLVNRRPCF  
SALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQ TALV  
ELVKHKPKATKEQLKAVMDDFAAFVEKCKADDKETCF AE  
EGKKLVAAASQAALGLDYKDDDDKGHHHHHHHHGGQ

## Precautions and Disclaimer

This product is for R&D use only, not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

## Preparation Instructions

Briefly centrifuge the vial before opening. It is recommended to reconstitute the protein in sterile ultrapure water to a final concentration of 100 µg/mL.

## Storage/Stability

Store the lyophilized product at -20 °C. The product is stable for at least 2 years as supplied. After reconstitution, it is recommended to store the protein in working aliquots at -20 °C.

## References

1. Thomas, L., Clinical Laboratory Diagnostics. 1st ed. Frankfurt: TH-Books Verlagsgesellschaft 652-3 (1998).
2. Ware, L.B. et al., Renal cortical albumin gene induction and urinary albumin excretion in response to acute kidney injury. *Am. J. Physiol. Renal Physiol.*, **300** (3), 628-38 (2011).
3. Lopez-Giacoman, S. et al., Biomarkers in chronic kidney disease, from kidney function to kidney damage. *World J. Nephrol.*, **4** (1), 57-73 (2015).
4. Andersen, S. et al., Glomerular permselectivity in early stages of overt diabetic nephropathy. *Kidney Int.*, **58** (5), 2129-37 (2000).

## Notice

We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.

The information in this document is subject to change without notice and should not be construed as a commitment by the manufacturing or selling entity, or an affiliate. We assume no responsibility for any errors that may appear in this document.

### Technical Assistance

Visit the tech service page at [SigmaAldrich.com/techservice](https://SigmaAldrich.com/techservice).

### Standard Warranty

The applicable warranty for the products listed in this publication may be found at [SigmaAldrich.com/terms](https://SigmaAldrich.com/terms).

### Contact Information

For the location of the office nearest you, go to [SigmaAldrich.com/offices](https://SigmaAldrich.com/offices).

The life science business of Merck operates as MilliporeSigma in the U.S. and Canada.

Merck, FLAG, SILu, and Sigma-Aldrich are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.  
MSST0011dat Rev 06/21

